Wilcox Mark H, Heaton Dave, Mulgirigama Aruni, Joshi Ashish V, Chirikov Viktor, Gibbons Daniel C, Webb David, Marston Xiaocong L, Alexander Myriam Na, Mitrani-Gold Fanny S
Department of Microbiology, University of Leeds, Leeds, UK.
Leeds Teaching Hospitals NHS Trust, Leeds, UK.
BJGP Open. 2025 Jul 23;9(2). doi: 10.3399/BJGPO.2024.0214. Print 2025.
Uncomplicated urinary tract infections (uUTIs) are common bacterial infections.
To evaluate the burden of uUTI in England for 1) potential determinants of disease progression; 2) extent and impact of antimicrobial prescribing non-concordant with treatment guidelines; and 3) healthcare burden and economic costs.
DESIGN & SETTING: Retrospective cohort study utilising patient data (January 2017-February 2020) from the Clinical Practice Research Datalink (CPRD) linked to English Hospital Episode Statistics.
Female patients aged ≥12 years with a new uUTI between 2018 and 2019, ≥14 months' continuous CPRD enrolment (≥12 months baseline, ≥2 months follow-up), and ≥1 oral antibiotic prescription ±5 days of uUTI diagnosis were included. Baseline characteristics were described in patients with or without disease progression (hospitalisation for acute pyelonephritis, bacteraemia, or sepsis). Treatment non-concordance with current English guidelines was assessed. Burden (all-cause and urinary tract infection-related healthcare resource use [HCRU] and costs) was evaluated in a 1:1 age and comorbidity-matched uUTI-free cohort.
Of 120 519 patients, 207 (0.2%) had disease progression requiring hospitalisation (during index uUTI episode); determinants included older age, index uUTI home consultation, prior hospitalisation, and medications prescribed for comorbid conditions in the prior 12 months ( classes: cardiovascular system, eye, and other drugs and preparations). Non-concordant treatment was observed in 43.5% of patients. All-cause HCRU burden and costs were significantly higher in patients with uUTI versus age and comorbidity-matched controls (<0.001) at 28 days (£160.06 versus £37.63) and in the 12-month follow-up (£1206.77 versus £460.97).
All-cause HCRU burden and costs were significantly higher in patients with uUTI versus matched controls (<0.001). Hospitalisation for acute pyelonephritis, bacteraemia, or sepsis following uUTI was uncommon.
单纯性尿路感染(uUTIs)是常见的细菌感染。
评估英格兰uUTI的负担,包括1)疾病进展的潜在决定因素;2)抗菌药物处方与治疗指南不一致的程度和影响;3)医疗负担和经济成本。
利用临床实践研究数据链(CPRD)中与英格兰医院事件统计数据相关的患者数据(2017年1月至2020年2月)进行回顾性队列研究。
纳入2018年至2019年间患有新发uUTI、年龄≥12岁、连续纳入CPRD≥14个月(基线≥12个月,随访≥2个月)且在uUTI诊断前后±5天内有≥1次口服抗生素处方的女性患者。描述有或无疾病进展(因急性肾盂肾炎、菌血症或败血症住院)患者的基线特征。评估与当前英国指南不一致的治疗情况。在年龄和合并症匹配的无uUTI队列中评估负担(全因和尿路感染相关的医疗资源使用[HCRU]及成本)。
在120519例患者中,207例(0.2%)出现需要住院治疗的疾病进展(在首次uUTI发作期间);决定因素包括年龄较大、首次uUTI在家咨询、既往住院以及在过去12个月中为合并症开具的药物(类别:心血管系统、眼部以及其他药物和制剂)。43.5%的患者存在治疗不依从情况。在28天时(160.06英镑对37.63英镑)以及12个月随访期内(1206.77英镑对460.97英镑),与年龄和合并症匹配的对照组相比,uUTI患者的全因HCRU负担和成本显著更高(<0.001)。
与匹配的对照组相比,uUTI患者的全因HCRU负担和成本显著更高(<0.001)。uUTI后因急性肾盂肾炎、菌血症或败血症住院的情况并不常见。